{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-088952","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.385607+00:00","generated_at":"2026-05-31T13:54:02.479082+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BridgeBio Q2 net loss $73.5M ($0.39/sh), NDA for acoramidis filed with PDUFA Nov 29","bullets":["Net loss $73.5M ($0.39/sh) vs $157.9M loss a year ago; Q2 revenue $2.2M, H1 revenue $213.3M from Bayer and Kyowa Kirin deals.","Acoramidis NDA for ATTR-CM accepted; PDUFA date Nov 29, 2024; 42% reduction in composite CVH and ACM events at Month 30.","Cash, equivalents, marketable securities and short-term restricted cash $587.2M as of June 30, up from $392.6M at Dec 31, 2023.","Phase 3 FORTIFY study (BBP-418 for LGMD2I/R9) surpassed interim analysis enrollment target; top-line data expected 2025.","Infigratinib in achondroplasia: +2.50 cm/yr annualized height velocity at Month 18 (p=0.0015), significant body proportionality improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-088952","json":"https://secwatch.observer/filing/0000950170-24-088952.json","markdown":"https://secwatch.observer/filing/0000950170-24-088952.md","text":"https://secwatch.observer/filing/0000950170-24-088952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024088952/0000950170-24-088952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024088952/bbio-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:54:02.479082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}